{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:42Z","timestamp":1792525242018,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12149-026-02256-3","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:14:54Z","timestamp":1783750494000},"page":"1395-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative SPECT imaging for predicting therapeutic response to lutetium-177 DOTATATE in neuroendocrine tumors"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7236-5025","authenticated-orcid":false,"given":"Yuichiro","family":"Furuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isanori","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2256_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jhbp.225","volume":"22","author":"T Ito","year":"2015","unstructured":"Ito T, Lee L, Hijioka M, Kawabe K, Kato M, Nakamura K, et al. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan. J Hepatobiliary Pancreat Sci. 2015;22:574\u20137. https:\/\/doi.org\/10.1002\/jhbp.225.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2256_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"key":"2256_CR3","doi-asserted-by":"publisher","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","volume":"4","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4:e2124750. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24750.","journal-title":"JAMA Netw Open"},{"key":"2256_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel). 2019;12:114. https:\/\/doi.org\/10.3390\/ph12030114.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2256_CR5","unstructured":"Oonishi H, Motomura N, Matsutomo N. Nuclear Medicine Technology. 4th edition. Tokyo: Ohmsha; 2021. pp. 468\u2009\u2013\u200973."},{"key":"2256_CR6","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s12149-021-01674-9","volume":"35","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Ann Nucl Med. 2021;35:1332\u201341. https:\/\/doi.org\/10.1007\/s12149-021-01674-9.","journal-title":"Ann Nucl Med"},{"key":"2256_CR7","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u201330. https:\/\/doi.org\/10.1200\/JCO.2007.15.2553.","journal-title":"J Clin Oncol"},{"key":"2256_CR8","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"key":"2256_CR9","doi-asserted-by":"publisher","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752-63. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6. Erratum in: Lancet Oncol. 2022;23:e59. doi: 10.1016\/S1470-2045(22)00028-6.","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2256_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI procedure standard for somatostatin receptor\u2013based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med. 2019;60:937\u201343. https:\/\/doi.org\/10.2967\/jnumed.118.230607.","journal-title":"J Nucl Med"},{"key":"2256_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2967\/jnumed.123.265987","volume":"65","author":"M Mileva","year":"2024","unstructured":"Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of 177Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective Phase II LUMEN Study. J Nucl Med. 2024;65:236\u201344. https:\/\/doi.org\/10.2967\/jnumed.123.265987.","journal-title":"J Nucl Med"},{"key":"2256_CR12","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"2256_CR13","doi-asserted-by":"publisher","unstructured":"Okamoto K, Hijioka S, Kobayashi N, Imaoka H, Hara K, Takeuchi S et al. Japan Oncology Network in Hepatobiliary and Pancreas. Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N). J Gastroenterol. 2026 Mar 23. https:\/\/doi.org\/10.1007\/s00535-026-02396-3. Epub ahead of print. PMID: 41866411.","DOI":"10.1007\/s00535-026-02396-3"},{"key":"2256_CR14","volume-title":"Digestive System Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2019","unstructured":"WHO Classification of Tumours Editorial Board. Digestive System Tumours. 5th ed. Lyon: IARC; 2019.","edition":"5"},{"key":"2256_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"5","key":"2256_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MNM.0000000000002110","volume":"47","author":"H Shimizu","year":"2026","unstructured":"Shimizu H, Furuya Y, Asai T, Iwama I, Tachibana H, Ishiguro Y, et al. Predicting eligibility for outpatient 177 Lu-DOTATATE-targeted radionuclide therapy in patients with neuroendocrine tumors. Nucl Med Commun. 2026;47(5):503\u20139. Epub 2026 Jan 15. PMID: 41536178.","journal-title":"Nucl Med Commun"},{"key":"2256_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K, et al. MIRD Pamphlet 26: Joint EANM\/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med. 2016;57:151\u201362. https:\/\/doi.org\/10.2967\/jnumed.115.159012.","journal-title":"J Nucl Med"},{"key":"2256_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13246-021-00983-7","volume":"44","author":"M Tsujimoto","year":"2021","unstructured":"Tsujimoto M, Shirakawa S, Watanabe M, Teramoto A, Uno M, Ota S, et al. Two-versus three-dimensional regions of interest for quantifying SPECT-CT images. Phys Eng Sci Med. 2021;44:365\u201375. https:\/\/doi.org\/10.1007\/s13246-021-00983-7.","journal-title":"Phys Eng Sci Med"},{"key":"2256_CR19","volume-title":"Radiobiology for the radiologist","author":"EJ Hall","year":"2018","unstructured":"Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 8th ed. Philadelphia: Wolters Kluwer; 2018.","edition":"8"},{"key":"2256_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MNM.0000000000000854","volume":"39","author":"M Tsujimoto","year":"2018","unstructured":"Tsujimoto M, Shirakawa S, Teramoto A, Ishiguro M, Nakane K, Ida Y, et al. Fluctuation of quantitative values on acquisition time and the reconstruction conditions in 99mTc-SPECT. Nucl Med Commun. 2018;39:601\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000000854.","journal-title":"Nucl Med Commun"},{"key":"2256_CR21","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.3390\/cancers14143317","volume":"14","author":"S Hasegawa","year":"2022","unstructured":"Hasegawa S, Kobayashi N, Wild D, Kaul F, Okubo N, Suzuki A, et al. Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors. Cancers (Basel). 2022;14:3317. https:\/\/doi.org\/10.3390\/cancers14143317.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2256_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/0971-6203.56081","volume":"34","author":"LG Marcu","year":"2009","unstructured":"Marcu LG, Bezak E. Radiobiological modeling of interplay between accelerated repopulation and altered fractionation schedules in head and neck cancer. J Med Phys. 2009;34(4):206\u201311. https:\/\/doi.org\/10.4103\/0971-6203.56081 . PMID: 20098550; PMCID: PMC2807142.","journal-title":"J Med Phys"},{"issue":"3","key":"2256_CR23","doi-asserted-by":"publisher","first-page":"e13443","DOI":"10.1111\/jne.13443","volume":"37","author":"H Sorbye","year":"2025","unstructured":"Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J. PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). J Neuroendocrinol. 2025;37(3):e13443. https:\/\/doi.org\/10.1111\/jne.13443 . Epub 2024 Sep 7. PMID: 39243213; PMCID: PMC11919471.","journal-title":"J Neuroendocrinol"},{"key":"2256_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13550-025-01250-6","volume":"15","author":"I Megherbi","year":"2025","unstructured":"Megherbi I, Hoog C, Perrier M, Brixi H, Cadiot G, Hoeffel-Fornes C, et al. Quantitative 177Lu-DOTATATE SPECT\/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study. EJNMMI Res. 2025;15:53. https:\/\/doi.org\/10.1186\/s13550-025-01250-6.","journal-title":"EJNMMI Res"},{"key":"2256_CR25","doi-asserted-by":"publisher","unstructured":"Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14(7):2012-8. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0934. PMID: 18381939.","DOI":"10.1158\/1078-0432.CCR-07-0934"},{"key":"2256_CR26","unstructured":"World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48; 1979."},{"key":"2256_CR27","doi-asserted-by":"publisher","unstructured":"Lin TC, Huang CH, Lien MY, Cheng FM, Li KC, Lin CY, et al. Tumor Volume Reduction Rate to Induction Chemotherapy is a Prognostic Factor for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Cohort Study. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221107714. PMID: 35770906; PMCID: PMC9252009. https:\/\/doi.org\/10.1177\/15330338221107714","DOI":"10.1177\/15330338221107714"},{"issue":"1","key":"2256_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1186\/s12885-020-07581-y","volume":"20","author":"T Masui","year":"2020","unstructured":"Masui T, Ito T, Komoto I, Uemoto S, JNETS Project Study Group. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20(1):1104. https:\/\/doi.org\/10.1186\/s12885-020-07581-y . PMID: 33189127; PMCID: PMC7666508.","journal-title":"BMC Cancer"},{"issue":"1","key":"2256_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13550-018-0386-4","volume":"8","author":"J Kurth","year":"2018","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Stegger L, Sch\u00e4fers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018;8(1):32. https:\/\/doi.org\/10.1186\/s13550-018-0386-4 . PMID: 29651569; PMCID: PMC5897276.","journal-title":"EJNMMI Res"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02256-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02256-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02256-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:03:31Z","timestamp":1792523011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02256-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02256-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}}]}}